The FDA's regulatory decisions will greatly affect the viability of the biosimilars market in the U.S., former FDA official Dr. Scott Gottlieb and Avalere Health Senior Vice President Gillian Woollett write. The significant promise of biologic breakthroughs for better patient care will be at risk if policymakers enforce blunt measures that limit prices and access to treatments, they write. Policies that diminish market-based incentives could compromise the position of the U.S. as global leader in biopharmaceutical innovation.

Full Story:

Related Summaries